Core Master Regulators of Glioblastoma Stem Cells
Patent Number: WO2018211409A1
Executive Summary:
General Description:
Targeting glioblastoma is challenging because there are few known regulator genes that control glioblastoma stem cells without also regulating normal brain cells. This invention identifies eight master regulator genes in the stem and proliferative factor categories. By targeting factors from both categories, it was possible to inhibit tumor growth and aggressiveness in mouse models. These promising results may be relevant for treatment of glioblastoma in humans.
Scientific Progress:
Successful in mouse models.
Future Directions:
Strengths:
Weaknesses:
Patent Status:
Legal status: Pending
Publication PMID: 27930300, 26074073
Publications:
Gujar AD, Le S, Mao DD, et al. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):E8247-E8256.
Mao DD, Gujar AD, Mahlokozera T, et al. A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. Cell Rep. 2015 Jun 23;11(11):1809-21.
Inventor Bio: David Tran
https://technologylicensing.research.ufl.edu/inventors/18595829_david-tran
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Pending
- Patent Link: https://patents.google.com/patent/WO2018211409A1
- Research Institute: University of Florida
- Disease Focus: Glioblastoma
- Basis of Invention: Target and inhibit the growth of glioblastoma stem cells to treat glioblastoma without harming normal brain cells
- How it works: Blocking eight core proteins that fall into either the stem category, which turns normal cells into glioblastoma stem cells, or the proliferative factor category, which regulates uncontrolled, malignant cell growth
- Lead Challenge Inventor: David Tran
- Inventors: David Tran, Son B. Le
- Development Stage: Preclinical
- Novelty:
- Newly identified regulators in glioblastoma
- Determined combinations of factors from the stem and proliferative factor categories to inhibit in order to prevent tumor growth and disease progression
- Clinical Applications:
- Targeted glioblastoma therapy that inhibits the growth of glioblastoma stem cells without affecting normal brain cells
General Description:
Targeting glioblastoma is challenging because there are few known regulator genes that control glioblastoma stem cells without also regulating normal brain cells. This invention identifies eight master regulator genes in the stem and proliferative factor categories. By targeting factors from both categories, it was possible to inhibit tumor growth and aggressiveness in mouse models. These promising results may be relevant for treatment of glioblastoma in humans.
Scientific Progress:
Successful in mouse models.
Future Directions:
- Clinical validation
Strengths:
- Suppresses both proliferative and stem factors
- Targets the expression of crucial cancer regulator genes
- Specifically targets only glioblastoma stem cells
Weaknesses:
- Not yet tested in humans
Patent Status:
Legal status: Pending
- Priority date: 2017-05-15
- Filing date: 2018-05-15
- Publication date: 2018-11-22
Publication PMID: 27930300, 26074073
Publications:
Gujar AD, Le S, Mao DD, et al. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):E8247-E8256.
Mao DD, Gujar AD, Mahlokozera T, et al. A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. Cell Rep. 2015 Jun 23;11(11):1809-21.
Inventor Bio: David Tran
https://technologylicensing.research.ufl.edu/inventors/18595829_david-tran
